Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination

Purpose of reviewThis review discusses progress in understanding the impact of immune tolerance on inducing broadly neutralizing antibodies (bnAbs), and how such knowledge can be incorporated into novel immunization approaches. Recent findingsOver 120 bnAbs have now been isolated, all of which bear unusual features associated with host tolerance controls, but paradoxically may also be required for their function. Evidence that poly/autoreactivity of membrane proximal external region bnAbs can invoke such controls has been demonstrated by knock-in technology, highlighting its potential for studying the impact of tolerance in the generation of bnAb lineages to distinct HIV-1 envelope targets. The requirement for extensive affinity maturation in developing neutralization breadth/potency during infection is being examined, and similar studies in the setting of immunization will be aided by testing novel vaccine approaches in knock-in models that either selectively express reverted V(D)J rearrangements, or unrearranged germline segments, from which bnAb lineages originate. SummaryIt is increasingly apparent that immune tolerance, sometimes invoked by self-reactivity that overlaps with bnAb epitope specificity, adds to a formidable set of roadblocks impeding bnAb induction. The path to an effective HIV-1 vaccine may thus benefit from a deeper understanding of host controls, including categorizing those that are unique or common at distinct bnAb targets, and ranking those most feasible to overcome by immunization. Ultimately, such emerging information will be critical to incorporate into new vaccine approaches that can be tested in human trials.

[1]  S. Elledge,et al.  Autoreactivity and Exceptional CDR Plasticity (but Not Unusual Polyspecificity) Hinder Elicitation of the Anti-HIV Antibody 4E10 , 2013, PLoS pathogens.

[2]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[3]  T. Kepler,et al.  Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design , 2012, Journal of Virology.

[4]  Robin A. Weiss,et al.  Neutralizing antibodies to HIV-1 induced by immunization , 2013, The Journal of experimental medicine.

[5]  J. McCluskey,et al.  Tolerance through Indifference: Autoreactive B Cells to the Nuclear Antigen La Show No Evidence of Tolerance in a Transgenic Model 1 , 2003, The Journal of Immunology.

[6]  M. Nussenzweig,et al.  Predominant Autoantibody Production by Early Human B Cell Precursors , 2003, Science.

[7]  M Anthony Moody,et al.  Antibody polyspecificity and neutralization of HIV-1: a hypothesis. , 2006, Human antibodies.

[8]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[9]  D. Irvine,et al.  Immunogenicity of Membrane-bound HIV-1 gp41 Membrane-proximal External Region (MPER) Segments Is Dominated by Residue Accessibility and Modulated by Stereochemistry* , 2013, The Journal of Biological Chemistry.

[10]  V. Pascual,et al.  Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors , 2008, Proceedings of the National Academy of Sciences.

[11]  F. Pereyra,et al.  A method for identification of HIV gp140 binding memory B cells in human blood. , 2009, Journal of immunological methods.

[12]  H. Liao,et al.  Induction of Antibodies in Rhesus Macaques That Recognize a Fusion-Intermediate Conformation of HIV-1 gp41 , 2011, PloS one.

[13]  Peter D. Kwong,et al.  HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.

[14]  D. Burton,et al.  Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses , 2012, Science.

[15]  D. Burton,et al.  Immune Tolerance Negatively Regulates B Cells in Knock-In Mice Expressing Broadly Neutralizing HIV Antibody 4E10 , 2013, The Journal of Immunology.

[16]  R. Palacios,et al.  Human immunodeficiency virus infection and systemic lupus erythematosus. An unusual case and a review of the literature , 2002, Lupus.

[17]  D. Burton,et al.  Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers , 2009, PLoS pathogens.

[18]  Ron Diskin,et al.  Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.

[19]  R. Hardy,et al.  The site and stage of anti-DNA B-cell deletion , 1995, Nature.

[20]  Renate Kunert,et al.  Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies , 2005, Science.

[21]  J. Mascola,et al.  Structural Basis for HIV-1 Neutralization by 2F5-Like Antibodies m66 and m66.6 , 2013, Journal of Virology.

[22]  C. Goodnow Transgenic mice and analysis of B-cell tolerance. , 1992, Annual review of immunology.

[23]  Jesús Santos,et al.  Echocardiographic abnormalities and associated factors in a cohort of asymptomatic HIV-infected patients. , 2013, AIDS research and human retroviruses.

[24]  Yih-En Andrew Ban,et al.  Challenges for structure-based HIV vaccine design , 2009, Current opinion in HIV and AIDS.

[25]  Baoshan Zhang,et al.  Broad and potent neutralization of HIV-1 by a gp41-specific human antibody , 2012, Nature.

[26]  A. Trkola,et al.  Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies , 2005, Nature Medicine.

[27]  B. Haynes,et al.  HIV‐1 neutralizing antibodies: understanding nature's pathways , 2013, Immunological reviews.

[28]  Pascal Poignard,et al.  Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques , 2009, Nature Medicine.

[29]  J. Mascola,et al.  Anti-HIV B Cell Lines as Candidate Vaccine Biosensors , 2012, The Journal of Immunology.

[30]  H. Liao,et al.  Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance , 2009, Proceedings of the National Academy of Sciences.

[31]  Chaim A. Schramm,et al.  Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.

[32]  H. Liao,et al.  Induction of HIV-1 Broad Neutralizing Antibodies in 2F5 Knock-in Mice: Selection against Membrane Proximal External Region–Associated Autoreactivity Limits T-Dependent Responses , 2013, The Journal of Immunology.

[33]  M. Nussenzweig,et al.  Structural basis for germline gene usage of a potent class of antibodies targeting the CD4 binding site of HIV-1 gp120 , 2012, Retrovirology.

[34]  B. Haynes,et al.  Modulation of Nonneutralizing HIV-1 gp41 Responses by an MHC-Restricted TH Epitope Overlapping Those of Membrane Proximal External Region Broadly Neutralizing Antibodies , 2014, The Journal of Immunology.

[35]  Pojen P. Chen,et al.  The Role of Antibody Polyspecificity and Lipid Reactivity in Binding of Broadly Neutralizing Anti-HIV-1 Envelope Human Monoclonal Antibodies 2F5 and 4E10 to Glycoprotein 41 Membrane Proximal Envelope Epitopes1 , 2007, The Journal of Immunology.

[36]  T. Kepler,et al.  Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors , 2011, Journal of Virology.

[37]  D. Burton,et al.  Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions , 2010, Proceedings of the National Academy of Sciences.

[38]  M. McCarter,et al.  Mouse marginal zone B cells harbor specificities similar to human broadly neutralizing HIV antibodies , 2013, Proceedings of the National Academy of Sciences.

[39]  B. Haynes,et al.  Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution , 2010, Proceedings of the National Academy of Sciences.

[40]  Peter D. Kwong,et al.  The antigenic structure of the HIV gp120 envelope glycoprotein , 1998, Nature.

[41]  H. Liao,et al.  Stable Docking of Neutralizing Human Immunodeficiency Virus Type 1 gp41 Membrane-Proximal External Region Monoclonal Antibodies 2F5 and 4E10 Is Dependent on the Membrane Immersion Depth of Their Epitope Regions , 2009, Journal of Virology.

[42]  R. Hardy B-1 B Cell Development1 , 2006, The Journal of Immunology.

[43]  T. Kepler,et al.  An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. , 2014, The Journal of clinical investigation.

[44]  J. Mascola,et al.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. , 2012, Immunity.

[45]  Vicki C. Ashley,et al.  Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia , 2008, Journal of Virology.

[46]  Feng Gao,et al.  Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals , 2011, Journal of Virology.

[47]  T. Kepler,et al.  Somatic hypermutation in B cells: an optimal control treatment. , 1993, Journal of theoretical biology.

[48]  L. Morris,et al.  The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection , 2011, Journal of Virology.

[49]  B. Haynes,et al.  Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. , 2011, Current opinion in immunology.

[50]  Ron Diskin,et al.  Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120 , 2012, Proceedings of the National Academy of Sciences.

[51]  L. Stamatatos,et al.  Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies , 2013, The Journal of experimental medicine.

[52]  D. Wallace,et al.  False-positive human immunodeficiency virus testing in patients with lupus erythematosus. , 1993, Seminars in arthritis and rheumatism.

[53]  M. Carrington,et al.  Adjunctive Passive Immunotherapy in Human Immunodeficiency Virus Type 1-Infected Individuals Treated with Antiviral Therapy during Acute and Early Infection , 2007, Journal of Virology.

[54]  D. Burton,et al.  Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1 , 2010, Proceedings of the National Academy of Sciences.

[55]  B. R. Kaye Rheumatologic manifestations of infection with human immunodeficiency virus (HIV). , 1989, Annals of internal medicine.

[56]  D. Huang,et al.  HIV-1 gp120 impairs B cell proliferation by inducing TGF-β1 production and FcRL4 expression , 2013, Nature Immunology.

[57]  M. Shlomchik,et al.  Sites and stages of autoreactive B cell activation and regulation. , 2008, Immunity.

[58]  Lynn Morris,et al.  Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape , 2012, Nature Medicine.

[59]  H. Katinger,et al.  Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data , 2007, AIDS.

[60]  Dennis R. Burton,et al.  A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals , 2010, PLoS pathogens.

[61]  Tongqing Zhou,et al.  Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization , 2013, Cell.

[62]  D. Pisetsky,et al.  Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation , 1990, The Journal of experimental medicine.

[63]  Terri Wrin,et al.  Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm , 2009, Journal of Virology.

[64]  T. Nishikawa,et al.  Auto-reactive B cells against peripheral antigen, desmoglein 3, escape from tolerance mechanism. , 2004, International immunology.

[65]  Barney S. Graham,et al.  Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 , 2011, Journal of Virology.

[66]  Lynn Morris,et al.  Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? , 2009, Nature Medicine.

[67]  J. Mascola,et al.  Relationship between Antibody 2F5 Neutralization of HIV-1 and Hydrophobicity of Its Heavy Chain Third Complementarity-Determining Region , 2009, Journal of Virology.

[68]  M. Nussenzweig,et al.  Autoreactivity in human IgG+ memory B cells. , 2007, Immunity.

[69]  Eugene I. Shakhnovich,et al.  Optimality of Mutation and Selection in Germinal Centers , 2010, PLoS Comput. Biol..

[70]  Michael S. Seaman,et al.  HIV-1 Neutralization Coverage Is Improved by Combining Monoclonal Antibodies That Target Independent Epitopes , 2012, Journal of Virology.

[71]  C. Goodnow,et al.  Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens , 1991, Nature.

[72]  W. Blattner,et al.  In Vivo gp41 Antibodies Targeting the 2F5 Monoclonal Antibody Epitope Mediate Human Immunodeficiency Virus Type 1 Neutralization Breadth , 2009, Journal of Virology.

[73]  A. Fauci,et al.  Insights into B cells and HIV‐specific B‐cell responses in HIV‐infected individuals , 2013, Immunological reviews.

[74]  V. Stewart,et al.  RAG-2-deficient blastocyst complementation: an assay of gene function in lymphocyte development. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[75]  Thomas B Kepler,et al.  B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study , 2012, Nature Biotechnology.

[76]  T. Kepler,et al.  Differential Reactivity of Germ Line Allelic Variants of a Broadly Neutralizing HIV-1 Antibody to a gp41 Fusion Intermediate Conformation , 2011, Journal of Virology.

[77]  B. Haynes,et al.  Rescue of HIV-1 Broad Neutralizing Antibody-Expressing B Cells in 2F5 VH × VL Knockin Mice Reveals Multiple Tolerance Controls , 2011, The Journal of Immunology.

[78]  R. Wyatt,et al.  B Cells from Knock-in Mice Expressing Broadly Neutralizing HIV Antibody b12 Carry an Innocuous B Cell Receptor Responsive to HIV Vaccine Candidates , 2013, The Journal of Immunology.

[79]  T. Kepler,et al.  High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. , 2009, Journal of virological methods.

[80]  G. Sapiro,et al.  Molecular architecture of native HIV-1 gp120 trimers , 2008, Nature.

[81]  H. Liao,et al.  Role of HIV membrane in neutralization by two broadly neutralizing antibodies , 2009, Proceedings of the National Academy of Sciences.

[82]  N. Letvin,et al.  Report of a false-positive HIV test result and the potential use of additional tests in establishing HIV serostatus. , 2000, Archives of internal medicine.

[83]  T. Kepler,et al.  Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies , 2013, The Journal of experimental medicine.

[84]  S. Pillai,et al.  Marginal zone B cells. , 2005, Annual review of immunology.

[85]  J. Lifson,et al.  Distribution and three-dimensional structure of AIDS virus envelope spikes , 2006, Nature.

[86]  Jörn E. Schmitz,et al.  Polyclonal B Cell Differentiation and Loss of Gastrointestinal Tract Germinal Centers in the Earliest Stages of HIV-1 Infection , 2009, PLoS medicine.

[87]  James E. Crowe,et al.  Human Peripheral Blood Antibodies with Long HCDR3s Are Established Primarily at Original Recombination Using a Limited Subset of Germline Genes , 2012, PloS one.

[88]  T. Kepler,et al.  Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B Cell Sorting , 2011, PloS one.

[89]  Danielle L. Watt,et al.  Altered Ig Hypermutation Pattern and Frequency in Complementary Mouse Models of DNA Polymerase ζ Activity , 2012, The Journal of Immunology.

[90]  Q. Sattentau,et al.  Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design. , 2012, Journal of AIDS & clinical research.

[91]  Maxim N. Artyomov,et al.  Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation , 2010, Nature.

[92]  N. Klinman,et al.  Relative roles of somatic and darwinian evolution in shaping the antibody response , 2000, Immunologic research.

[93]  Development of prophylactic vaccines against HIV-1 , 2013, Retrovirology.

[94]  Leonardo Calza,et al.  Systemic and discoid lupus erythematosus in HIV-infected patients treated with highly active antiretroviral therapy , 2003, International journal of STD & AIDS.

[95]  S. Plotkin Correlates of Protection Induced by Vaccination , 2010, Clinical and Vaccine Immunology.

[96]  B. Haynes,et al.  Common Tolerance Mechanisms, but Distinct Cross-Reactivities Associated with gp41 and Lipids, Limit Production of HIV-1 Broad Neutralizing Antibodies 2F5 and 4E10 , 2013, The Journal of Immunology.

[97]  V. Brusic,et al.  HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. , 2008, Immunity.

[98]  Antonio Lanzavecchia,et al.  Broadly neutralizing antiviral antibodies. , 2013, Annual review of immunology.

[99]  Hanqin Peng,et al.  Mechanism of HIV-1 Neutralization by Antibodies Targeting a Membrane-Proximal Region of gp41 , 2013, Journal of Virology.

[100]  David Baltimore,et al.  Antibody-based Protection Against HIV Infection by Vectored ImmunoProphylaxis , 2011, Nature.

[101]  T. Kepler,et al.  Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated , 2011, The Journal of experimental medicine.

[102]  D. Nemazee,et al.  Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes , 1989, Nature.

[103]  David Nemazee,et al.  Rational immunogen design to target specific germline B cell receptors , 2012, Retrovirology.

[104]  M. Jackson,et al.  B cells are exquisitely sensitive to central tolerance and receptor editing induced by ultralow affinity, membrane-bound antigen , 1996, The Journal of experimental medicine.

[105]  Gwo-Yu Chuang,et al.  Antibodies VRC01 and 10E8 Neutralize HIV-1 with High Breadth and Potency Even with Ig-Framework Regions Substantially Reverted to Germline , 2014, The Journal of Immunology.

[106]  H. Liao,et al.  HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. , 2012, Trends in microbiology.

[107]  M. Altfeld,et al.  Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 , 2011, PLoS pathogens.